Status:
COMPLETED
The Prevalence of Pulmonary Hypertension in Patients With COVID-19.
Lead Sponsor:
Attgeno AB
Conditions:
Hypertension, Pulmonary
Right Ventricular Overload
Eligibility:
All Genders
18+ years
Brief Summary
The virus infection Covid-19 fills our hospitals and intensive care departments in a very unique way and there is a lack of essential insight into the pathophysiology of the disease. As a result, very...
Detailed Description
Demographics and data from study variables will be documented in paper CRFs at the investigational site. * Demography o Age, sex * Covid-19 related variables o COVID-19 diagnosis * Concomitant ...
Eligibility Criteria
Inclusion
- Men and women at least 18 years of age
- Diagnosed with COVID-19 and is treated at an intensive care unit.
Exclusion
- Responsible investigator considers that co-morbidity is so pronounced that it does not allow reasonable interpretation of data.
- Missing verified diagnosis of COVID-19
Key Trial Info
Start Date :
June 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 15 2020
Estimated Enrollment :
67 Patients enrolled
Trial Details
Trial ID
NCT04459364
Start Date
June 1 2020
End Date
July 15 2020
Last Update
January 11 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Karolinska University Hospital
Stockholm, Sweden, 17176